Igyxos’ IGX12 brings a fresh approach to infertility treatment, aiming to improve outcomes for both men and women.

Delve into Vandria's technology and its Alzheimer's candidate, VNA-318, the first mitophagy-based candidate in Alzheimer's in ...

A new wave of metabolic disease drugs beyond GLP-1 agonists is emerging to address the unmet needs of patients.

Discover six obesity deals made so far in 2025, with dealmaking activity in the field being largely dominated by big pharma companies.

While non-exhaustive, this list offers an overview of the year’s biotech events taking place around the world, aimed at partnering and connecting with decision makers in biopharma. If there is a ...

The U.K. has had a stronghold on the biopharma and healthcare industry for a long time and remains one of the top hubs for life science research. So, Merck’s decision to back out of its $1 billion ...

Research Triangle Park in North Carolina has emerged as one of the U.S’s most dynamic and rapidly expanding biotech hubs, home to a thriving ecosystem of established pharma companies, research ...

Developing treatments for neurological diseases presents a huge challenge for neuroscience companies within the biotech industry. The central nervous system (CNS) is extremely complex, and many ...

Discover the emergence of dual-payload ADCs and PDCs, which could mark a significant evolution in targeted therapeutics.

Asking whether China is the future of the biotech industry might seem counterintuitive, considering the current biotech geopolitical context. If you haven’t followed this series of events, a ...

The concept of de-extinction has been around for many years. Once considered a fanciful idea, recent advancements in technology – notably CRISPR – have made bringing back extinct animals such as ...